Red Foxglove Compound Shows Promise for Heart Failure Treatment
The DIGIT-HF trial demonstrated that adding digitoxin to standard heart failure treatment reduces the risk of death or hospitalization, with a good safety profile, suggesting that cardiac glycosides may be beneficial in modern heart failure management, especially in cost-constrained settings.